Variation in anthelmintic responses are driven by genetic differences among diverse C. elegans wild strains

• Published in: PLoS pathogens 2023-04, Vol.19 (4), p.e1011285-e1011285
• Main Authors: Shaver, Amanda O, Wit, Janneke, Dilks, Clayton M, Crombie, Timothy A, Li, Hanchen, Aroian, Raffi V, Andersen, Erik C
• Format: Article
• Language: English
• Subjects: Analysis; Animals; Anthelmintic agents; Anthelmintics; Anthelmintics - pharmacology; Antinematodal Agents - pharmacology; Antiparasitic agents; Benzimidazole; Benzimidazoles; Biology and Life Sciences; Caenorhabditis elegans; Dosage and administration; Drug dosages; Drug resistance; Drug Resistance - genetics; Drugs; Estimates; Genetic diversity; Genetic research; Genetic variation; Genetics; Genome-wide association studies; Genome-Wide Association Study; Genomes; Genomics; Health aspects; Heritability; Humans; Laboratories; Lactones; Livestock; Medicine and Health Sciences; Nematicides; Nematoda; Nematoda - genetics; Nematode Infections - drug therapy; Nematode Infections - genetics; Nematode Infections - parasitology; Nematodes; Parasite resistance; Parasites; Pest resistance; Prevention; Research and Analysis Methods; Risk factors; Roundworm infections; Variation
• ISSN: 1553-7374; 1553-7366; 1553-7374
• DOI: 10.1371/journal.ppat.1011285

Treatment of parasitic nematode infections in humans and livestock relies on a limited arsenal of anthelmintic drugs that have historically reduced parasite burdens. However, anthelmintic resistance (AR) is increasing, and little is known about the molecular and genetic causes of resistance for most drugs. The free-living roundworm Caenorhabditis elegans has proven to be a tractable model to understand AR, where studies have led to the identification of molecular targets of all major anthelmintic drug classes. Here, we used genetically diverse C. elegans strains to perform dose-response analyses across 26 anthelmintic drugs that represent the three major anthelmintic drug classes (benzimidazoles, macrocyclic lactones, and nicotinic acetylcholine receptor agonists) in addition to seven other anthelmintic classes. First, we found that C. elegans strains displayed similar anthelmintic responses within drug classes and significant variation across drug classes. Next, we compared the effective concentration estimates to induce a 10% maximal response (EC10) and slope estimates of each dose-response curve of each strain to the laboratory reference strain, which enabled the identification of anthelmintics with population-wide differences to understand how genetics contribute to AR. Because genetically diverse strains displayed differential susceptibilities within and across anthelmintics, we show that C. elegans is a useful model for screening potential nematicides before applications to helminths. Third, we quantified the levels of anthelmintic response variation caused by genetic differences among individuals (heritability) to each drug and observed a significant correlation between exposure closest to the EC10 and the exposure that exhibited the most heritable responses. These results suggest drugs to prioritize in genome-wide association studies, which will enable the identification of AR genes.